Pfizer Inc. (NYSE:PFE) Shares Purchased by Pure Financial Advisors Inc.

Pure Financial Advisors Inc. increased its position in shares of Pfizer Inc. (NYSE:PFE) by 1.7% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 24,154 shares of the biopharmaceutical company’s stock after acquiring an additional 400 shares during the quarter. Pure Financial Advisors Inc.’s holdings in Pfizer were worth $790,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in PFE. Orser Capital Management LLC boosted its position in Pfizer by 2.7% during the fourth quarter. Orser Capital Management LLC now owns 10,990 shares of the biopharmaceutical company’s stock worth $428,000 after acquiring an additional 290 shares during the last quarter. Capital Analysts LLC boosted its position in Pfizer by 5.2% during the fourth quarter. Capital Analysts LLC now owns 46,017 shares of the biopharmaceutical company’s stock worth $1,803,000 after acquiring an additional 2,258 shares during the last quarter. Pittenger & Anderson Inc. boosted its position in Pfizer by 0.6% during the fourth quarter. Pittenger & Anderson Inc. now owns 93,429 shares of the biopharmaceutical company’s stock worth $3,661,000 after acquiring an additional 516 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Pfizer by 205.9% in the 4th quarter. Renaissance Technologies LLC now owns 13,102,541 shares of the biopharmaceutical company’s stock valued at $513,358,000 after purchasing an additional 8,819,241 shares during the last quarter. Finally, Financial Advocates Investment Management boosted its holdings in shares of Pfizer by 0.5% in the 4th quarter. Financial Advocates Investment Management now owns 71,461 shares of the biopharmaceutical company’s stock valued at $2,799,000 after purchasing an additional 344 shares during the last quarter. Hedge funds and other institutional investors own 70.28% of the company’s stock.

In other news, EVP Douglas M. Lankler sold 65,000 shares of Pfizer stock in a transaction dated Wednesday, April 29th. The shares were sold at an average price of $37.85, for a total value of $2,460,250.00. Following the completion of the transaction, the executive vice president now directly owns 135,375 shares of the company’s stock, valued at approximately $5,123,943.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Jennifer B. Damico sold 2,181 shares of Pfizer stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $36.13, for a total transaction of $78,799.53. Following the completion of the transaction, the senior vice president now directly owns 7,542 shares of the company’s stock, valued at $272,492.46. The disclosure for this sale can be found here. Insiders sold a total of 69,362 shares of company stock valued at $2,622,691 over the last ninety days. Company insiders own 0.08% of the company’s stock.

Shares of PFE traded down $0.40 during midday trading on Wednesday, hitting $33.64. The company had a trading volume of 12,680,076 shares, compared to its average volume of 33,425,040. The company’s 50 day moving average price is $35.11 and its 200 day moving average price is $36.13. The stock has a market cap of $189.03 billion, a price-to-earnings ratio of 12.21, a PEG ratio of 2.70 and a beta of 0.68. Pfizer Inc. has a 52 week low of $27.88 and a 52 week high of $44.10. The company has a quick ratio of 0.78, a current ratio of 1.02 and a debt-to-equity ratio of 0.56.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, April 28th. The biopharmaceutical company reported $0.80 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.71 by $0.09. The company had revenue of $12.03 billion during the quarter, compared to the consensus estimate of $11.38 billion. Pfizer had a net margin of 31.17% and a return on equity of 25.76%. The company’s revenue was down 8.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.85 EPS. Equities analysts anticipate that Pfizer Inc. will post 2.88 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 31st will be given a $0.38 dividend. This represents a $1.52 annualized dividend and a dividend yield of 4.52%. The ex-dividend date of this dividend is Thursday, July 30th. Pfizer’s payout ratio is currently 51.53%.

PFE has been the topic of a number of research analyst reports. Morgan Stanley decreased their price target on shares of Pfizer from $43.00 to $36.00 and set an “equal weight” rating on the stock in a report on Thursday, April 2nd. SVB Leerink initiated coverage on shares of Pfizer in a report on Tuesday, June 16th. They issued a “market perform” rating and a $40.00 price target on the stock. Piper Sandler lifted their price target on shares of Pfizer from $18.50 to $24.00 in a report on Friday, June 26th. Mizuho started coverage on shares of Pfizer in a report on Monday, June 29th. They issued a “buy” rating and a $38.00 price target on the stock. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and set a $53.00 price target on shares of Pfizer in a research note on Thursday, March 19th. Ten analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $38.72.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Featured Article: What causes a stock to be most active?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.